1. Home
  2. FISI vs ANAB Comparison

FISI vs ANAB Comparison

Compare FISI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FISI
  • ANAB
  • Stock Information
  • Founded
  • FISI 1817
  • ANAB 2005
  • Country
  • FISI United States
  • ANAB United States
  • Employees
  • FISI N/A
  • ANAB N/A
  • Industry
  • FISI Major Banks
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • FISI Finance
  • ANAB Health Care
  • Exchange
  • FISI Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • FISI 522.5M
  • ANAB 621.1M
  • IPO Year
  • FISI 1999
  • ANAB 2017
  • Fundamental
  • Price
  • FISI $24.60
  • ANAB $23.17
  • Analyst Decision
  • FISI Buy
  • ANAB Buy
  • Analyst Count
  • FISI 3
  • ANAB 10
  • Target Price
  • FISI $33.00
  • ANAB $44.25
  • AVG Volume (30 Days)
  • FISI 108.0K
  • ANAB 775.6K
  • Earning Date
  • FISI 07-24-2025
  • ANAB 08-04-2025
  • Dividend Yield
  • FISI 5.03%
  • ANAB N/A
  • EPS Growth
  • FISI N/A
  • ANAB N/A
  • EPS
  • FISI N/A
  • ANAB N/A
  • Revenue
  • FISI $108,628,000.00
  • ANAB $111,872,000.00
  • Revenue This Year
  • FISI $101.16
  • ANAB N/A
  • Revenue Next Year
  • FISI $6.68
  • ANAB $24.39
  • P/E Ratio
  • FISI N/A
  • ANAB N/A
  • Revenue Growth
  • FISI N/A
  • ANAB 387.20
  • 52 Week Low
  • FISI $17.27
  • ANAB $12.21
  • 52 Week High
  • FISI $29.79
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • FISI 39.93
  • ANAB 56.01
  • Support Level
  • FISI $24.41
  • ANAB $22.46
  • Resistance Level
  • FISI $26.60
  • ANAB $24.17
  • Average True Range (ATR)
  • FISI 0.46
  • ANAB 1.72
  • MACD
  • FISI -0.19
  • ANAB -0.01
  • Stochastic Oscillator
  • FISI 8.68
  • ANAB 73.23

About FISI Financial Institutions Inc.

Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: